March 13, 2024 Ryvu Therapeutics S.A. Annual Report 2023
Read More
December 11, 2023 Presentation of preclinical data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting and additional clinical update
Read More
December 11, 2023 Preclinical and clinical data on RVU120 presented at the 2023 American Society of Hematology (ASH) Annual Meeting
Read More
December 7, 2023 Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023
Read More
November 29, 2023 Ryvu Therapeutics Q3 2023 Financial Report
Read More
November 2, 2023 Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting
Read More
October 23, 2023 Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update
Read More
October 20, 2023 Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes
Read More
October 16, 2023 RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023
Read More
October 16, 2023 Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Read More
October 4, 2023 Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Read More
September 14, 2023 Conclusion of an amendment to global License Agreement with Menarini Group
Read More
September 13, 2023 Ryvu Therapeutics H1 2023 Financial Report
Read More
August 4, 2023 Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology
Read More
July 31, 2023 Conclusion of a financing agreement with the Medical Research Agency
Read More
July 31, 2023 Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology
Read More
July 21, 2023 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
July 14, 2023 Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
Read More
July 6, 2023 Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
Read More
June 19, 2023 Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
Read More
Posts navigation
